113 related articles for article (PubMed ID: 28744813)
21. Toosendanin mediates cisplatin sensitization through targeting Annexin A4/ATP7A in non-small cell lung cancer cells.
Zheng MD; Wang ND; Li XL; Yan J; Tang JH; Zhao XH; Zhang Z
J Nat Med; 2018 Jun; 72(3):724-733. PubMed ID: 29627895
[TBL] [Abstract][Full Text] [Related]
22. CXCR4 promotes cisplatin-resistance of non-small cell lung cancer in a CYP1B1-dependent manner.
Xie S; Tu Z; Xiong J; Kang G; Zhao L; Hu W; Tan H; Tembo KM; Ding Q; Deng X; Huang J; Zhang Q
Oncol Rep; 2017 Feb; 37(2):921-928. PubMed ID: 27922681
[TBL] [Abstract][Full Text] [Related]
23. MicroRNA-106b-5p regulates cisplatin chemosensitivity by targeting polycystic kidney disease-2 in non-small-cell lung cancer.
Yu S; Qin X; Chen T; Zhou L; Xu X; Feng J
Anticancer Drugs; 2017 Sep; 28(8):852-860. PubMed ID: 28723865
[TBL] [Abstract][Full Text] [Related]
24. Autophagy Inhibition Overcomes the Antagonistic Effect Between Gefitinib and Cisplatin in Epidermal Growth Factor Receptor Mutant Non--Small-Cell Lung Cancer Cells.
Liu JT; Li WC; Gao S; Wang F; Li XQ; Yu HQ; Fan LL; Wei W; Wang H; Sun GP
Clin Lung Cancer; 2015 Sep; 16(5):e55-66. PubMed ID: 25979647
[TBL] [Abstract][Full Text] [Related]
25. Phloretin exhibits an anticancer effect and enhances the anticancer ability of cisplatin on non-small cell lung cancer cell lines by regulating expression of apoptotic pathways and matrix metalloproteinases.
Ma L; Wang R; Nan Y; Li W; Wang Q; Jin F
Int J Oncol; 2016 Feb; 48(2):843-53. PubMed ID: 26692364
[TBL] [Abstract][Full Text] [Related]
26. The MDM2-inhibitor Nutlin-3 synergizes with cisplatin to induce p53 dependent tumor cell apoptosis in non-small cell lung cancer.
Deben C; Wouters A; Op de Beeck K; van Den Bossche J; Jacobs J; Zwaenepoel K; Peeters M; Van Meerbeeck J; Lardon F; Rolfo C; Deschoolmeester V; Pauwels P
Oncotarget; 2015 Sep; 6(26):22666-79. PubMed ID: 26125230
[TBL] [Abstract][Full Text] [Related]
27. Sequential treatment with AT-101 enhances cisplatin chemosensitivity in human non-small cell lung cancer cells through inhibition of apurinic/apyrimidinic endonuclease 1-activated IL-6/STAT3 signaling pathway.
Ren T; Shan J; Qing Y; Qian C; Li Q; Lu G; Li M; Li C; Peng Y; Luo H; Zhang S; Zhang W; Wang D; Zhou SF
Drug Des Devel Ther; 2014; 8():2517-29. PubMed ID: 25548514
[TBL] [Abstract][Full Text] [Related]
28. Co-delivery of cisplatin and paclitaxel by folic acid conjugated amphiphilic PEG-PLGA copolymer nanoparticles for the treatment of non-small lung cancer.
He Z; Huang J; Xu Y; Zhang X; Teng Y; Huang C; Wu Y; Zhang X; Zhang H; Sun W
Oncotarget; 2015 Dec; 6(39):42150-68. PubMed ID: 26517524
[TBL] [Abstract][Full Text] [Related]
29. Akt1 inhibition by RNA interference sensitizes human non-small cell lung cancer cells to cisplatin.
Lee MW; Kim DS; Min NY; Kim HT
Int J Cancer; 2008 May; 122(10):2380-4. PubMed ID: 18224693
[TBL] [Abstract][Full Text] [Related]
30. SKA1 regulates the metastasis and cisplatin resistance of non-small cell lung cancer.
Shen L; Yang M; Lin Q; Zhang Z; Miao C; Zhu B
Oncol Rep; 2016 May; 35(5):2561-8. PubMed ID: 26985856
[TBL] [Abstract][Full Text] [Related]
31. Knockdown of REV3 synergizes with ATR inhibition to promote apoptosis induced by cisplatin in lung cancer cells.
Jiang HG; Chen P; Su JY; Wu M; Qian H; Wang Y; Li J
J Cell Physiol; 2017 Dec; 232(12):3433-3443. PubMed ID: 28075014
[TBL] [Abstract][Full Text] [Related]
32. Downregulation of miR-25 modulates non-small cell lung cancer cells by targeting CDC42.
Yang T; Chen T; Li Y; Gao L; Zhang S; Wang T; Chen M
Tumour Biol; 2015 Mar; 36(3):1903-11. PubMed ID: 25432132
[TBL] [Abstract][Full Text] [Related]
33. CK2 inhibitors enhance the radiosensitivity of human non-small cell lung cancer cells through inhibition of stat3 activation.
Lin YC; Hung MS; Lin CK; Li JM; Lee KD; Li YC; Chen MF; Chen JK; Yang CT
Cancer Biother Radiopharm; 2011 Jun; 26(3):381-8. PubMed ID: 21711111
[TBL] [Abstract][Full Text] [Related]
34. Involvement of endothelial CK2 in the radiation induced perivascular resistant niche (PVRN) and the induction of radioresistance for non-small cell lung cancer (NSCLC) cells.
Li Q; Zong Y; Li K; Jie X; Hong J; Zhou X; Wu B; Li Z; Zhang S; Wu G; Meng R
Biol Res; 2019 Apr; 52(1):22. PubMed ID: 30992075
[TBL] [Abstract][Full Text] [Related]
35. Cisplatin-induced apoptosis in non-small-cell lung cancer cells is dependent on Bax- and Bak-induction pathway and synergistically activated by BH3-mimetic ABT-263 in p53 wild-type and mutant cells.
Matsumoto M; Nakajima W; Seike M; Gemma A; Tanaka N
Biochem Biophys Res Commun; 2016 Apr; 473(2):490-6. PubMed ID: 26996126
[TBL] [Abstract][Full Text] [Related]
36. The modifier subunit of glutamate cysteine ligase relates to cisplatin resistance in human small cell lung cancer xenografts in vivo.
Nishi M; Abe Y; Fujimori S; Hamamoto A; Inoue Y; Miyazaki N; Oida Y; Ikoma N; Ohnishi Y; Yamazaki H; Ueyama Y; Nakamura M
Oncol Rep; 2005 Aug; 14(2):421-4. PubMed ID: 16012725
[TBL] [Abstract][Full Text] [Related]
37. Phosphorylation of eIF2α suppresses cisplatin-induced A549 cell apoptosis via p38 inhibition.
Guo L; Chen R; Ma N; Xiao H; Chen Y; Chen F; Mei J; Ding F; Zhong H
Cancer Biother Radiopharm; 2013 May; 28(4):268-73. PubMed ID: 23570372
[TBL] [Abstract][Full Text] [Related]
38. Downregulation of miR-101 contributes to epithelial-mesenchymal transition in cisplatin resistance of NSCLC cells by targeting ROCK2.
Ye Z; Yin S; Su Z; Bai M; Zhang H; Hei Z; Cai S
Oncotarget; 2016 Jun; 7(25):37524-37535. PubMed ID: 27229528
[TBL] [Abstract][Full Text] [Related]
39. Survival data for postoperative adjuvant chemotherapy comprising cisplatin plus vinorelbine after complete resection of non-small cell lung cancer.
Kenmotsu H; Ohde Y; Wakuda K; Nakashima K; Omori S; Ono A; Naito T; Murakami H; Kojima H; Takahashi S; Isaka M; Endo M; Takahashi T
Cancer Chemother Pharmacol; 2017 Sep; 80(3):609-614. PubMed ID: 28761967
[TBL] [Abstract][Full Text] [Related]
40. MKP1/CL100 controls tumor growth and sensitivity to cisplatin in non-small-cell lung cancer.
Chattopadhyay S; Machado-Pinilla R; Manguan-García C; Belda-Iniesta C; Moratilla C; Cejas P; Fresno-Vara JA; de Castro-Carpeño J; Casado E; Nistal M; Gonzalez-Barón M; Perona R
Oncogene; 2006 Jun; 25(23):3335-45. PubMed ID: 16462770
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]